Skip to main content
Clinical Trials/KCT0009605
KCT0009605
Not yet recruiting
未知

A Prospective, Comparative Study to investigate the Clinical Efficacy of iLUX and IPL treatment in Dry Eye Patients with Meibomian gland dysfunction

Asan Medical Center0 sites140 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Asan Medical Center
Enrollment
140
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients who visited Asan Medical Center between IRB approval date and March 30, 2025 (3 months prior to June 30, 2025\) and were diagnosed with dry eye syndrome with MGD and voluntarily agreed to participate in clinical trials.
  • 2\) Mild to moderate dry eye syndrome with MGD is diagnosed by the following criteria.
  • i. symptoms of dry eye syndrome persist for at least 3 months before registration of clinical trial
  • ii. The TBUT is less than 10 seconds and meets at least one of the following three criteria
  • a. Meibomian gland secretion is reduced during eyelid compression, showing turbid, toothpaste\-like secretions, or viscous secretions.
  • b. Two or more telangiectasia at the edge of your eyelid
  • c. Two or more orifices for meibomian gland are blocked
  • 3\) Age 19 years and older and under 85 years of any gender or race
  • 4\) Ocular surface disease index (OSDI) score of 33 or lower (mild to moderate OSDI score)

Exclusion Criteria

  • 1\) Sjogren’s disease
  • 2\) all the orifices of the upper and lower meibomian glands are completely blocked and no secretion of meibum
  • 3\) Subject with use of cyclosporine, steroids, or antibiotics (eye drops) within 2 weeks of the screening day.
  • 4\) Subject with use of eye drops containing lipid within 2 weeks of the screening day.
  • 5\) Wearing contact lenses within the six month of screening day.
  • 6\) Ophthalmic surgery or trauma within the last 3 months of screening day.
  • 7\) Subject planning eye surgery (including LASIK/LASEK) during the study period
  • 8\) Pregnant women, lactating women and planning to pregnant women
  • 9\) Allergic to fluorescein eye drops.
  • 10\) Other things that are not suitable judged by an investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials